11 News by Biotec Pharmacon

Tip: You can further refine your news selection by topics, departments and industries.

11 News by Biotec Pharmacon

Tip: You can further refine your news selection by topics, departments and industries.

Biotec Pharmacon reports on neuroblastoma study

19-Jul-2011 - Biotec Pharmacon ASA is announcing the final results from an early phase (I/II) study on combining Soluble Beta-Glucan (SBG) with anti-cancer antibodies in treatment of neuroblastoma in children. The study, performed at Memorial Sloan-Kettering Cancer Center, showed that the combined treatment ...

antibodies cancer neuroblastoma

Biotec Pharmacon receives promising interim results from animal study

27-Jan-2011 - Biotec Pharmacon ASA has received an interim data report from the second animal study in diabetic mice. The results confirm the finding from the first study showing that a 2% aqueous solution of SBG has good wound healing capability. An important goal with the second study was to investigate ...

wound healing

Svein Lien appointed new CEO of Biotec Pharmacon ASA

12-Mar-2010 - Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010. Svein Lien (55) joins the company with a financial background and extensive experience from ...

diagnostic products

Biotec Pharmacon: Phase III results with SBG for diabetic foot ulcer not positive

24-Nov-2009 - Biotec Pharmacon has received the results from both its phase III studies with SBG for diabetic foot ulcer and regrets to inform that the results are not positive. The studies failed to show superiority of SBG vs. placebo in terms of ulcer healing, and the company will thus not proceed with the ...

diabetic foot ulcers oral mucositis phase III studies

Jan Buch Andersen heading up newly established Biotec Marine Biochemicals AS

18-Jun-2009 - Biotec Pharmacon ASA has moved all its enzyme activities into Biotec Marine Biochemicals AS and hired Jan Buch Andersen as Managing Director of the newly established subsidiary. The target is to strengthen the development of the marine enzymes business, which in 2009 is expected to generate ...

biochemicals enzymes molecular biology

Biotec Pharmacon: Phase III diabetic ulcer program proceeds as planned after interim analysis

15-May-2009 - The independent statistician responsible for the interim analysis of the second of the two phase III studies with SBG for diabetic foot ulcers recommends that Biotec Pharmacon proceeds as planned with the study. As no adjustments are being made to sample size, patient enrolment is already ...

diabetic foot ulcers phase III studies ulcer

Biotec Pharmacon's SBG shows promising effect in animal model for inflammatory bowel disease

27-Mar-2009 - Researchers at Rikshospitalet University Hospital has presented an abstract from an animal study with SBG for treatment of inflammatory bowel disease on the 3rd World Immune Regulation Meeting in Davos, Switzerland. The study demonstrated that orally administered SBG reduced colitis-associated ...

colitis ulcerosa Crohn's disease inflammatory bowel disease

Biotec Pharmacon: Patient inclusion started in phase III Oral Mucositis study

20-Oct-2008 - Patient inclusion has commenced as planned in the first of two phase III studies for the use of Biotec Pharmacon's SBG in patients with oral mucositis. This is a common and potentially severe side-effect of radiotherapy for cancer, in particular for head and neck cancers. Biotec Pharmacon expect ...

neck cancer oral mucositis phase III studies

Immunocorp Animal Health AS secures major research contract

18-Aug-2008 - Immunocorp Animal Health AS (IAH), a wholly owned subsidiary of Biotec Pharmacon ASA, has been awarded a major research and development contract by the European Commission. The contract will be undertaken by nine partners from Norway, the Netherlands, Denmark, England, Germany and Poland and is ...

Denmark Germany Netherlands

New clinical study for treatment of diabetic foot ulcers

28-Feb-2006 - Biotec Pharmacon has entered into an agreement with Nottingham City Hospital NHS Trust to perform a clinical phase II study entitled "A randomised, double-blind, placebo-controlled study to determine the efficacy of soluble beta-1,3/1,6-glucan in chronic foot ulcers in diabetes." A total of 104 ...

diabetic foot ulcers immune cells
Search all
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,276 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now